Grünenthal partners with Max-Planck in hunt for neurological candidates

Stolberg-based drugmaker Grünenthal has entered into a collaboration with fellow German groups Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) to develop novel therapies for the neurological disorder Charcot-Marie-Tooth 1A (CMT1A).

Grünenthal says that the collaboration will combine “the disease proficiency of MPI-EM, the drug discovery expertise of LDC and Grünenthal's competency in drug discovery and development.”

The groups will establish a novel screening platform to identify small molecule modulators to generate innovative drug candidates, with research costs split equally between Grünenthal and Max Planck Society.